Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 361 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bladder, Overactive Clear all
Terminated Phase 4 Interventional Results available

Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection

NCT03508921
View directory record Official record
Conditions
Overactive Bladder, Urinary Tract Infections
Interventions
Periprocedural Antibiotics, Extended Antibiotics, Injection of OnabotulinumtoxinA (BTX-A)
Drug · Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 22, 2026, 4:42 AM EDT
Terminated Phase 4 Interventional Results available

Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen

NCT01003249
View directory record Official record
Conditions
Overactive Bladder, Constipation, Lower Urinary Tract Symptoms
Interventions
Baclofen, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 64 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 22, 2026, 4:42 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

NCT00439140
View directory record Official record
Conditions
Overactive Bladder
Interventions
botulinum toxin Type A, Normal Saline (Placebo)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 24, 2014 · Synced Oct 22, 2026, 4:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial

NCT05308979
View directory record Official record
Conditions
Overactive Bladder, Urinary Urge Incontinence, Overactive Bladder Syndrome, Urinary Incontinence, Urge, Urge Incontinence, Urinary Urgency, Urinary Frequency
Interventions
OnabotulinumtoxinA 100 UNT [Botox]
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 22, 2026, 4:42 AM EDT
Completed Phase 4 Interventional

Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder

NCT00224146
View directory record Official record
Conditions
Overactive Bladder, Urinary Incontinence, Quality of Life
Interventions
oxybutynin transdermal delivery system (Oxytrol(r))
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,878 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
10
States / cities
Mobile, Alabama • Tucson, Arizona • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2011 · Synced Oct 22, 2026, 4:42 AM EDT
Terminated Not applicable Interventional

Electrophysiologic Mapping of the Bladder

NCT02041442
View directory record Official record
Conditions
Electrical Evaluation of Urinary Bladder
Interventions
Electrical mapping of the urinary bladder
Procedure
Lead sponsor
Englewood Hospital and Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 22, 2026, 4:42 AM EDT
Completed Phase 4 Interventional

Lidocaine for Pain After Urodynamic Testing

NCT03390790
View directory record Official record
Conditions
Voiding Disorders, Overactive Bladder, Urinary Incontinence
Interventions
Lidocaine gel 2%, Standard lubricant gel
Drug · Other
Lead sponsor
Atlantic Health System
Other
Eligibility
40 Years to 80 Years · Female only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 19, 2019 · Synced Oct 22, 2026, 4:42 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder

NCT00773552
View directory record Official record
Conditions
Urinary Urge, Urge Incontinence, Overactive Bladder
Interventions
solifenacin succinate, placebo
Drug
Lead sponsor
Stamford Hospital
Other
Eligibility
20 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 22, 2026, 4:42 AM EDT
Not listed Not applicable Interventional

The Use of cineMRI to Evaluate Botox in Patients With Medication Refractory Overactive Bladder

NCT02315950
View directory record Official record
Conditions
Overactive Bladder
Interventions
Botulinum toxin and cineMRI-UDS
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
21 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 22, 2026, 4:42 AM EDT
Terminated Phase 4 Interventional

Use of Percutaneous Tibial Nerve Stimulation With Solifenacin or Placebo to Treat Refractory Overactive Bladder

NCT01764893
View directory record Official record
Conditions
Overactive Bladder
Interventions
PTNS plus solifenacin, Placebo
Other
Lead sponsor
Bay State Clinical Trials, Inc.
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 23, 2014 · Synced Oct 22, 2026, 4:42 AM EDT
Completed Not applicable Interventional Results available

Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction

NCT06059066
View directory record Official record
Conditions
Neurogenic Bladder, Lower Urinary Tract Symptoms, Overactive Bladder, Neuro: Neurogenic Bladder, Neurogenic Detrusor Overactivity
Interventions
Standard number of injection sites, Reduced number of injection sites
Procedure
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 22, 2026, 4:42 AM EDT
Withdrawn Phase 4 Interventional

Prophylactic Analgesia for Bladder Botox Injections

NCT06514430
View directory record Official record
Conditions
Urinary Incontinence, Urinary Incontinence, Urge, Overactive Bladder
Interventions
Phenazopyridine, 1% lidocaine with sodium bicarbonate
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 22, 2026, 4:42 AM EDT
Completed Phase 3 Interventional

A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)

NCT00454896
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
VESIcare®, placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
65
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Atherton, California + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 22, 2026, 4:42 AM EDT
Terminated Phase 3 Interventional Results available

Local Anesthetic Treatments for Overactive Bladder

NCT00427648
View directory record Official record
Conditions
Overactive Bladder
Interventions
alkalinized xylocaine, placebo
Drug
Lead sponsor
Frank Tu
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Evanston, Illinois • Park City, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 22, 2026, 4:42 AM EDT
Withdrawn Phase 4 Interventional

The Combined Effect of Intravesical Botox Injections and HoLEP Surgery in Treating Benign Prostatic Hyperplasia and Overactive Bladder

NCT05393921
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Overactive Bladder
Interventions
Intravesical Botox injection
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Cleveland, Ohio • Lyndhurst, Ohio • Richmond Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 22, 2026, 4:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mapping of the Human Brainstem During Continence and Micturition: Noninvasive 7-T fMRI Study

NCT04846387
View directory record Official record
Conditions
Healthy
Interventions
Magnetic Resonance Imaging (MRI), Post-Void Residual, Uroflowmetry, Questionaire - AUA Symptom Score
Diagnostic Test · Behavioral
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 22, 2026, 4:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

LURN: Urinary Urgency Phenotyping Protocol

NCT04557748
View directory record Official record
Conditions
Lower Urinary Tract Symptoms
Interventions
Observational, Observational Controls, Central Sensitization, Physical Activity and Sleep Tracker, Physical Activity and Sleep Tracker Controls, Organ-Based, Qualitative Assessment of Patients with Urinary Urgency
Other
Lead sponsor
Arbor Research Collaborative for Health
Other
Eligibility
18 Years and older
Enrollment
1,030 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
6
States / cities
Chicago, Illinois • Iowa City, Iowa • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 22, 2026, 4:42 AM EDT
Completed Phase 4 Interventional

Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects

NCT00413790
View directory record Official record
Conditions
Healthy
Interventions
Darifenacin, Tolterodine, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
162 participants
Timeline
2006 – 2007
U.S. locations
12
States / cities
Scottsdale, Arizona • Tempe, Arizona • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 22, 2026, 4:42 AM EDT
Not listed Phase 4 Interventional

BOTOX® at the Time of Prolapse Surgery for OAB

NCT04807920
View directory record Official record
Conditions
Urinary Bladder, Overactive, Pelvic Organ Prolapse
Interventions
OnabotulinumtoxinA 100 UNT, Injectable saline
Drug · Other
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 22, 2026, 4:42 AM EDT
Withdrawn Phase 4 Interventional

Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women

NCT02981459
View directory record Official record
Conditions
Urinary Frequency/Urgency, Bladder Irritable, Bladder Pain Syndrome
Interventions
Mirabegron
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 89 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 22, 2026, 4:42 AM EDT
Enrolling by invitation No phase listed Observational

Migraine Medication Effects on Urinary Symptoms

NCT06212661
View directory record Official record
Conditions
Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders, Overactive Bladder Syndrome, Overactive Detrusor, Migraine, Interstitial Cystitis
Interventions
Ubrogepant, Rimegepant, Atogepant, Eptinezumab, Fremanezumab, Galcanezumab, Erenumab, Botulinum toxin A
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 4:42 AM EDT
Completed Not applicable Interventional Results available

Posterior Tibial Nerve Stimulation's Effectiveness in UI Frequency in Overactive Patients in Home

NCT03595215
View directory record Official record
Conditions
Overactive Bladder
Interventions
TENS
Device
Lead sponsor
Theranova, L.L.C.
Industry
Eligibility
55 Years to 100 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 21, 2021 · Synced Oct 22, 2026, 4:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Overactive Bladder Telemedicine Non-inferiority Trial

NCT05117918
View directory record Official record
Conditions
Overactive Bladder
Interventions
SUFU Clinical Care Pathway for Overactive Bladder, Telemedicine
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 22, 2026, 4:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Percutaneous Tibial Nerve Stimulation Maintenance: Monthly Therapy or Per Patient Requested Need

NCT03136601
View directory record Official record
Conditions
Overactive Bladder
Interventions
PTNS maintenance
Other
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 22, 2026, 4:42 AM EDT